Validation of the CAMCOG-DS-II, a neuropsychological test battery for Alzheimer's disease in people with Down syndrome : A Horizon 21 European Down syndrome Consortium study
Ivain, P. (King's College London)
Baksh, A. (King's College London)
Saini, F. (King's College London)
Idris, M. (King's College London)
Tamayo-Elizalde, M. (King's College London)
Wells, J. (King's College London)
Benejam, Bessy (Fundació Catalana Síndrome de Down)
Loosli, S.V. (University Hospital Zurich (Suïssa))
Sandkühler, K. (LMU University Hospital)
Wlasich, E. (LMU University Hospital)
Wagemann, O. (LMU University Hospital)
Levin, J. (LMU University Hospital)
Martet, D. (Institut Jêrome Lejeune)
Sacco, Simona (Institut Jêrome Lejeune)
Falquero, S. (Institut Jêrome Lejeune)
Clert, M. (Institut Jêrome Lejeune)
Rebillat, Anne-Sophie (Institut Jêrome Lejeune)
Khoo, W.M. (University of Cambridge)
Smith, M.A. (University of Cambridge)
Beresford-Webb, J. (University of Cambridge)
Zaman, Shahid (University of Cambridge)
Carmona Iragui, María (Institut de Recerca Sant Pau)
Videla Toro, Laura (Institut de Recerca Sant Pau)
Fortea, Juan (Institut de Recerca Sant Pau)
Langballe, E.M. (Oslo University Hospital (Oslo, Noruega))
Medbøen, I.T. (University of Oslo)
Larsen, F.K. (University of Oslo)
Baldimtsi, E. (Greek Association of Alzheimer's Disease and Related Disorders (GAADRD))
Paradisi, R. (Aristotle University of Thessaloniki)
Ntailakis, P. (Greek Association of Alzheimer's Disease and Related Disorders (GAADRD))
Tsolaki, Magda (Aristotle University of Thessaloniki)
Papantoniou, G. (University of Ioannina)
McGlinchey, E. (Trinity College Dublin)
McCarron, M. (University Hospital. Tallaght)
Kennelly, S. (University Hospital. Tallaght)
Strydom, A. (King's College London)
Universitat Autònoma de Barcelona

Date:	2025
Abstract:	INTRODUCTION: The Cambridge Cognitive Examination modified for use in people with Down syndrome (CAMCOG-DS) is a sensitive cognitive test for Alzheimer's disease (AD)-related decline in people with DS, but needs updates for sensitivity, cultural adaptability, and additional memory/executive function items. This study aimed to develop and validate the CAMCOG-DS-II. METHODS: In this multi-language, multi-site study, the psychometric properties of the CAMCOG-DS-II were evaluated against previously validated measures in 223 participants (mean age: 40. 18 years) with DS across seven countries. RESULTS: The CAMCOG-DS-II had a high completion rate, minimal floor/ceiling effects (compared to the modified Cued Recall Test, the CANTAB Paired Associates Learning, and the Purdue Pegboard), strong validity and reliability, and performance was unaffected by language across sites. It differentiated between those with/without AD and distinguished clinically rated cognitively stable and prodromal individuals. CONCLUSION: The CAMCOG-DS-II is a sensitive measure of cognitive performance in people with DS at risk of AD. Its cross-language and site reliability support its potential use in AD-DS clinical trials. Highlights: Developed and validated the Cambridge Cognitive Examination modified for use in people with Down syndrome (CAMCOG-DS-II) for Alzheimer's disease in Down syndrome. CAMCOG-DS-II shows increased sensitivity to Alzheimer's disease-related decline in Down syndrome. Improved applicability across an international and culturally diverse population. Differentiates Alzheimer's disease status: cognitively stable, prodromal, and clinical.
Grants:	Instituto de Salud Carlos III PI20/01473 Instituto de Salud Carlos III PI23/01786 Instituto de Salud Carlos III PI18/00335 Instituto de Salud Carlos III ICI23/00032
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Alzheimer's disease ; Down syndrome ; Cognitive decline ; Cognitive testing ; Trisomy 21
Published in:	Alzheimer's & dementia, Vol. 21 Núm. 3 (march 2025) , p. e70071, ISSN 1552-5279

DOI: 10.1002/alz.70071
PMID: 40145416

17 p, 449.6 KB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Recerca Sant Pau
Articles > Research articles
Articles > Published articles